Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 24:2020:7537924.
doi: 10.1155/2020/7537924. eCollection 2020.

5-2-1 Criteria: A Simple Screening Tool for Identifying Advanced PD Patients Who Need an Optimization of Parkinson's Treatment

D Santos-García  1 , T de Deus Fonticoba  2 , E Suárez Castro  2 , A Aneiros Díaz  2 , D McAfee  3
Affiliations

5-2-1 Criteria: A Simple Screening Tool for Identifying Advanced PD Patients Who Need an Optimization of Parkinson's Treatment

D Santos-García et al. Parkinsons Dis. .

Abstract

Objective: 5- (5 times oral levodopa tablet taken/day) 2- (2 hours of OFF time/day) 1- (1 hour/day of troublesome dyskinesia) criteria have been proposed by a Delphi expert consensus panel for diagnosing advanced Parkinson's disease (PD). The aim of the present study is to compare quality of life (QoL) in PD patients with "5-2-1 positive criteria" vs QoL in PD patients without "5-2-1 positive criteria" (defined as meeting ≥1 of the criteria).

Methods: This is a cross-sectional, observational, monocenter study. Three different instruments were used to assess QoL: the 39-Item Parkinson's Disease Quality of Life Questionnaire Summary Index Score (PDQ-39SI); a subjective rating of perceived QoL (PQ-10); and the EUROHIS-QOL 8-Item Index (EUROHIS-QOL8).

Results: From a cohort of 102 PD patients (65.4 ± 8.2 years old, 53.9% males; disease duration 4.7 ± 4.5 years), 20 (19.6%) presented positive 5-2-1 criteria: 6.9% for 5, 17.6% for 2, and 4.9% for 1. 37.5% (12/32) and 25% (5/20) of patients with motor complications and dyskinesia, respectively, presented 5-2-1 negative criteria. Both health-related (PDQ-39SI, 25.6 ± 14 vs 12.1 ± 9.2; p < 0.0001) and global QoL (PQ-10, 6.1 ± 2 vs 7.1 ± 1.3; p=0.007; EUROHIS-QOL8, 3.5 ± 0.5 vs 3.7 ± 0.4; p=0.034) were worse in patients with 5-2-1 positive criteria. Moreover, nonmotor symptoms burden (Non-Motor Symptoms Scale total score, 64.8 ± 44.8 vs 39.4 ± 35.1; p < 0.0001) and autonomy for activities of daily living (ADLS scale, 73.5 ± 13.1 vs 89.2 ± 9.3; p < 0.0001) were worse in patients with 5-2-1 positive criteria. Patient's principal caregiver's strain (Caregiver Stain Index, 4.3 ± 3 vs 1.5 ± 1.6; p < 0.0001), burden (Zarit Caregiver Burden Inventory, 28.4 ± 12.5 vs 10.9 ± 9.8; p < 0.0001), and mood (Beck Depression Inventory II, 12.2 ± 7.2 vs 6.2 ± 6.1; p < 0.0001) were worse in patients with 5-2-1 positive criteria as well.

Conclusions: QoL is worse in patients meeting ≥1 of the 5-2-1 criteria. This group of patients and their caregivers are more affected as a whole. These criteria could be useful for identifying patients in which it is necessary to optimize Parkinson's treatment.

PubMed Disclaimer

Conflict of interest statement

D. Santos-García has received honoraria for educational presentations and advice service by AbbVie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial and Teva. T. de Deus Fonticoba has received honoraria for educational presentations and advice service by AbbVie. The other authors declare that they have no conflicts of interest.

References

    1. Antonini A., Isaias I. U., Rodolfi G., et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. Journal of Neurology. 2011;258(4):579–585. doi: 10.1007/s00415-010-5793-z. - DOI - PubMed
    1. Von Campenhausen S., Bornschein B., Wick R., et al. Prevalence and incidence of Parkinson’s disease in Europe. European Neuropsychopharmacology. 2005;15(4):473–490. doi: 10.1016/j.euroneuro.2005.04.007. - DOI - PubMed
    1. Braak H., Tredici K. D., Rüb U., de Vos R. A. I., Jansen Steur E. N. H., Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging. 2003;24(2):197–211. doi: 10.1016/s0197-4580(02)00065-9. - DOI - PubMed
    1. Kulisevsky J., Luquin M. R., Arbelo J. M., et al. Enfermedad de Parkinson avanzada. Características clínicas y tratamiento (parte I) Neurología. 2013;28(8):503–521. doi: 10.1016/j.nrl.2013.05.001. - DOI - PubMed
    1. Antonini A., Martinez-Martin P., Odin P., Ray Chaudhuri K. P1.229 Improvement of motor and non-motor symptoms after switching from oral therapy to continuous duodenal levodopa infusion in advanced Parkinson’s disease. Parkinsonism & Related Disorders. 2009;15(Suppl 4):S88–S100. doi: 10.1016/s1353-8020(09)70844-2. - DOI

LinkOut - more resources